Predictors for eltrombopag response in patients with hepatitis C virus-associated thrombocytopenia
Tamer A Elbedewy,1 Mohamed A Elsebaey,1 Samah A Elshweikh,1 Heba Elashry,2 Sherief Abd-Elsalam2 1Internal Medicine Department, Faculty of Medicine, Tanta University, Tanta, Egypt; 2Tropical Medicine Department, Faculty of Medicine, Tanta University, Tanta, Egypt Background and aims: Thrombocytopen...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2019-02-01
|
Series: | Therapeutics and Clinical Risk Management |
Subjects: | |
Online Access: | https://www.dovepress.com/predictors-for-eltrombopag-response-in-patients-with-hepatitis-c-virus-peer-reviewed-article-TCRM |
_version_ | 1818718416256630784 |
---|---|
author | Elbedewy TA Elsebaey MA Elshweikh SA Elashry H Abd-Elsalam S |
author_facet | Elbedewy TA Elsebaey MA Elshweikh SA Elashry H Abd-Elsalam S |
author_sort | Elbedewy TA |
collection | DOAJ |
description | Tamer A Elbedewy,1 Mohamed A Elsebaey,1 Samah A Elshweikh,1 Heba Elashry,2 Sherief Abd-Elsalam2 1Internal Medicine Department, Faculty of Medicine, Tanta University, Tanta, Egypt; 2Tropical Medicine Department, Faculty of Medicine, Tanta University, Tanta, Egypt Background and aims: Thrombocytopenia is a common hematological abnormality observed in patients infected with hepatitis C virus (HCV). The use of eltrombopag has been approved for HCV-associated thrombocytopenia. This is the first study aiming to determine the predictive factors of response to eltrombopag therapy in patients with HCV-associated thrombocytopenia. Patients and methods: This prospective study was carried out on 130 patients with chronic HCV-associated thrombocytopenia (<50,000×109/L) that precludes the initiation of HCV therapy. Eltrombopag was initiated at a dose of 25 mg once daily; the dose was adjusted with 25 mg increments every 2 weeks to achieve the target platelet count. The primary end point was to achieve stable target platelet count (50,000–100,000×109/L) required to initiate antiviral therapy. Results: Treatment response was achieved in 111 (85.38%) patients. This prospective study showed that megakaryocyte hypoplasia or aplasia and splenectomy were independent risk factors for eltrombopag nonresponse in chronic HCV-associated thrombocytopenic patients. Conclusion: Eltrombopag is safe and effective for patients with HCV-associated thrombocytopenia. Bone marrow examination should be considered before initiating treatment with eltrombopag in chronic HCV-associated thrombocytopenic patients, especially in patients with splenectomy. Keywords: HCV, therapy, thrombocytopenia, predictors, splenectomy, direct-acting antivirals, DAAs |
first_indexed | 2024-12-17T19:50:42Z |
format | Article |
id | doaj.art-053e15128f6a48b8aa54899dcad949c6 |
institution | Directory Open Access Journal |
issn | 1178-203X |
language | English |
last_indexed | 2024-12-17T19:50:42Z |
publishDate | 2019-02-01 |
publisher | Dove Medical Press |
record_format | Article |
series | Therapeutics and Clinical Risk Management |
spelling | doaj.art-053e15128f6a48b8aa54899dcad949c62022-12-21T21:34:43ZengDove Medical PressTherapeutics and Clinical Risk Management1178-203X2019-02-01Volume 1526927444020Predictors for eltrombopag response in patients with hepatitis C virus-associated thrombocytopeniaElbedewy TAElsebaey MAElshweikh SAElashry HAbd-Elsalam STamer A Elbedewy,1 Mohamed A Elsebaey,1 Samah A Elshweikh,1 Heba Elashry,2 Sherief Abd-Elsalam2 1Internal Medicine Department, Faculty of Medicine, Tanta University, Tanta, Egypt; 2Tropical Medicine Department, Faculty of Medicine, Tanta University, Tanta, Egypt Background and aims: Thrombocytopenia is a common hematological abnormality observed in patients infected with hepatitis C virus (HCV). The use of eltrombopag has been approved for HCV-associated thrombocytopenia. This is the first study aiming to determine the predictive factors of response to eltrombopag therapy in patients with HCV-associated thrombocytopenia. Patients and methods: This prospective study was carried out on 130 patients with chronic HCV-associated thrombocytopenia (<50,000×109/L) that precludes the initiation of HCV therapy. Eltrombopag was initiated at a dose of 25 mg once daily; the dose was adjusted with 25 mg increments every 2 weeks to achieve the target platelet count. The primary end point was to achieve stable target platelet count (50,000–100,000×109/L) required to initiate antiviral therapy. Results: Treatment response was achieved in 111 (85.38%) patients. This prospective study showed that megakaryocyte hypoplasia or aplasia and splenectomy were independent risk factors for eltrombopag nonresponse in chronic HCV-associated thrombocytopenic patients. Conclusion: Eltrombopag is safe and effective for patients with HCV-associated thrombocytopenia. Bone marrow examination should be considered before initiating treatment with eltrombopag in chronic HCV-associated thrombocytopenic patients, especially in patients with splenectomy. Keywords: HCV, therapy, thrombocytopenia, predictors, splenectomy, direct-acting antivirals, DAAshttps://www.dovepress.com/predictors-for-eltrombopag-response-in-patients-with-hepatitis-c-virus-peer-reviewed-article-TCRMThrombocytopeniaHCVeltrombobagpredictors |
spellingShingle | Elbedewy TA Elsebaey MA Elshweikh SA Elashry H Abd-Elsalam S Predictors for eltrombopag response in patients with hepatitis C virus-associated thrombocytopenia Therapeutics and Clinical Risk Management Thrombocytopenia HCV eltrombobag predictors |
title | Predictors for eltrombopag response in patients with hepatitis C virus-associated thrombocytopenia |
title_full | Predictors for eltrombopag response in patients with hepatitis C virus-associated thrombocytopenia |
title_fullStr | Predictors for eltrombopag response in patients with hepatitis C virus-associated thrombocytopenia |
title_full_unstemmed | Predictors for eltrombopag response in patients with hepatitis C virus-associated thrombocytopenia |
title_short | Predictors for eltrombopag response in patients with hepatitis C virus-associated thrombocytopenia |
title_sort | predictors for eltrombopag response in patients with hepatitis c virus associated thrombocytopenia |
topic | Thrombocytopenia HCV eltrombobag predictors |
url | https://www.dovepress.com/predictors-for-eltrombopag-response-in-patients-with-hepatitis-c-virus-peer-reviewed-article-TCRM |
work_keys_str_mv | AT elbedewyta predictorsforeltrombopagresponseinpatientswithhepatitiscvirusassociatedthrombocytopenia AT elsebaeyma predictorsforeltrombopagresponseinpatientswithhepatitiscvirusassociatedthrombocytopenia AT elshweikhsa predictorsforeltrombopagresponseinpatientswithhepatitiscvirusassociatedthrombocytopenia AT elashryh predictorsforeltrombopagresponseinpatientswithhepatitiscvirusassociatedthrombocytopenia AT abdelsalams predictorsforeltrombopagresponseinpatientswithhepatitiscvirusassociatedthrombocytopenia |